Schizophrenia Genetics: A New Gene-Network Approach Reveals 641 Hidden Risk Genes

For decades, schizophrenia genetics was like looking for a light under a lamppost—searching for risk genes only in the immediate vicinity of known DNA landmarks. A groundbreaking study published in Nature Genetics on June 22, 2026 has shattered that limitation, revealing 641 previously unrecognized genes associated with the disorder by mapping how genes communicate across long genomic distances .

How the Gene-Network Approach Works

A consortium led by the Lieber Institute for Brain Development, in collaboration with the University of Bari and over 60 psychiatric hospitals worldwide, developed a new computational method that looks beyond individual genes to map how networks of genes communicate across the brain . Traditional genome-wide association studies (GWAS) only examine genetic variants that lie in the immediate vicinity of known genes. The new approach uses long-range co-expression networking to capture regulatory relationships between distant genetic elements—similar to how social networks connect people who don't live next door to each other .

The scale of the analysis was enormous: the team analyzed genetic data from over 102,000 individuals and brain tissue samples from hundreds of donors across six different brain regions . By building network maps of which genes are co-expressed across these regions, the method could pull out signals that standard approaches missed entirely .

Why Standard Methods Missed These Genes

The researchers described the previous approach as "looking for the light under the lamppost" . Most of a gene's regulatory influence comes from long-distance variants located far away on the chromosome. Standard GWAS tools only scan the immediate neighborhood of known genes, ignoring these distant but critical regulatory connections .

The new method captures these long-range regulatory relationships, allowing the detection of 641 new candidate genes that had been invisible in standard analyses .

How This Builds on Prior Genetic Studies

To understand why this discovery matters, it helps to see how the field evolved:

The GWAS era (2000s–2020s): Large consortia like the Psychiatric Genomics Consortium identified 108 distinct genetic loci associated with schizophrenia and established it as a highly polygenic disorder involving both common variants of small effect and rare copy number variants . These findings were a critical first step, but they produced statistical signals—not causal genes or an explanation of how genes work together .

Early network approaches (2010s–2024): Previous research used co-expression networks and protein-interaction networks to find gene modules linked to schizophrenia . The Lieber Institute itself had previously shown that schizophrenia risk genes need to partner with about 20 other genes to produce illness , and found that nearby genes carry their own additive risk through guilt-by-association effects . But these earlier attempts were largely limited to short-range genomic interactions .

The new advance: By modeling long-range co-expression networks across multiple brain regions, the new method transformed statistical GWAS "hits" into a functional map of coordinated gene programs . This revealed 641 new candidate genes and specific biological pathways: glutamate signaling, synaptic communication, immune processes, and brain development .

Implications for Precision Psychiatry

The findings move the field decisively toward network-based precision medicine. Instead of treating schizophrenia as a single disease caused by one or a few genes, the results suggest that individual patients may have disruptions in different gene-network subprograms. Treatments could eventually be tailored to a person's specific network profile .

As Dr. Daniel Weinberger, CEO of the Lieber Institute, put it: "Understanding these coordinated genetic programs brings us closer to precision psychiatry, where treatments can be tailored to an individual's specific biological profile" .

The identified pathways—particularly glutamate signaling and synaptic function—also point to concrete molecular targets for developing new classes of drugs . This aligns with parallel discoveries in the field, including new techniques for identifying risk genes from weaker statistical signals and the discovery of how rare gene mutations like ZNF136 and STAG1 drive schizophrenia risk .

What Comes Next

This network-based approach is part of a broader shift in psychiatric genetics. Simultaneously, researchers are using 3D chromatin mapping to understand how distant regulatory elements physically loop together to control gene expression , and multi-omics integration that combines transcriptomics, neuroimaging, and clinical data . The Lieber Institute's breakthrough provides the road map: turning a list of genetic risk factors into a functional circuit diagram of the disease—and ultimately, into personalized treatments for individual patients.